TY  - JOUR
PY  - 2005//
TI  - Selective serotonin reuptake inhibitors and the risk for suicidality in adolescents: an update
JO  - International journal of adolescent medicine and health
A1  - Giner, Lucas
A1  - Nichols, C. Matthew
A1  - Zalsman, Gil
A1  - Oquendo, Maria A.
SP  - 211
EP  - 220
VL  - 17
IS  - 3
N2  - The controversy regarding Selective Serotonin Reuptake Inhibitors (SSRIs) and suicidality dates back to the early 1990s. The first agent reported to be associated with suicidality was fluoxotine. In 2003, the British Medicines and Healthcare Products Regulatory Agency (MHRA) warned about possible risk of suicidality in children and adolescents treated with paroxetine for Major Depressive Disorder (MDD). This warning was soon extended to all the SSRIs as well as venlafaxine and mirtazapine. Similarly, the United States Food and Drug Administration (FDA) issued a "black box warning" on these medications in 2004. We address the debate concerning this warning and its clinical implications and review the latest contributions to the literature.<p />  <p>Language: en</p>
LA  - en
SN  - 0334-0139
UR  - http://dx.doi.org/
ID  - ref1
ER  -